Celltrion reveals Phase 3 clinical trial result of Herzuma at world’s largest oncology conference

Published: 2017-06-08 16:30:00
Updated: 2017-06-08 13:20:44

Celltrion announced a result of the clinical trials of Herzuma(project name: CT-P6), an antibody biosimilar for the treatment of breast cancer, and Truxima(project name: CT-P10), a biosimilar for the treatment of hematological malignancy, at the American Society of Clinical Oncology in Chicago on...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.